Achievement of steady state [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2020-06-12 12:17 (1502 d 04:33 ago) – Posting: # 21530
Views: 1,689

Hi Roy,

❝ Please Help!!!


Is your  !  key jammed?

❝ Please find Below detail for my question,


Since you posted in this category, see also this post #3. Please do your homework first.

Dosing Day: Day 1 to Day 8.

Blood Sample collection on: Day 4 to Last time Point for both period.


You mean on days 4 and 8, right?

Wash out: 10 Days.


Doesn’t make sense. If you attain (pseudo) steady state on day 4, you can immediately switch to the other treatment. EMA MR-GL (2014):

In steady-state studies, the washout period of the previous treatment can overlap with the build-up of the second treatment (direct switching), provided the build-up period is sufficiently long (at least 5 times the terminal half-life).


❝ Pre-dose Blood sample collection for Day1, Day2 and Day3 are required?


On all days.
EMA:

Whether the steady-state has been achieved is assessed by comparing at least three pre-dose concentrations for each formulation. The apparent half-life should also be taken into account.

FDA ANDA draft (2013):

We recommend that if a steady-state study is recommended, applicants carry out appropriate dosage administration and sampling to document the attainment of steady-state.


There was a consensus at two GBHI-workshops (Amsterdam, April 2018; Bethesda, December 2019) that a statistical assessment is not required. See this presentation.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,117 posts in 4,859 threads, 1,647 registered users;
38 visitors (1 registered, 37 guests [including 9 identified bots]).
Forum time: 16:50 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5